07:00 , Jul 13, 2015 |  BC Week In Review  |  Financial News

Capstone Therapeutics proposes private placement of units

Capstone Therapeutics Corp. (OTCQB:CAPS), Tempe, Ariz.   Business: Musculoskeletal, Dermatology   Date announced: 2015-06-26   Type: Private placement of units   To be raised: Up to $10 million   Units: TBD   Price prior: $0.21...
07:00 , Jun 15, 2015 |  BioCentury  |  Regulation

LDL in context

Discussion at last week's advisory committee meeting for the PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab suggest that, for first-in-class hypercholesterolemia candidates, the agency and the committee are leaning toward narrowing the use of LDL...
08:00 , Jan 5, 2015 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa data

LipimetiX Development LLC and Capstone reported pooled data from a double-blind, placebo-controlled, Australian Phase Ia trial and a double-blind, placebo-controlled, Australian Phase Ib/IIa trial in patients with refractory hypercholesterolemia and healthy volunteers with elevated fasting...
07:00 , Jun 16, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ib/IIa ongoing

LipimetiX Development LLC began the multiple ascending-dose portion of a double-blind, placebo-controlled, Australian Phase Ib/IIa trial of IV AEM-28 in 15 patients with refractory hypercholesterolemia. Per protocol, the second portion began after the single ascending-dose...
07:00 , Apr 21, 2014 |  BC Week In Review  |  Clinical News

AEM-28: Phase Ia started

LipimetiX Development LLC began a double-blind, placebo-controlled, Australian Phase Ia trial to evaluate single and multiple ascending-doses of IV AEM-28 in about 36 healthy volunteers with elevated cholesterol. LipimetiX Development is a JV between Capstone...
07:00 , Sep 16, 2013 |  BioCentury  |  Finance

Benu's virtual play

Benu's virtual play New investment firm Benu BioVentures has the backing of a single investor to establish virtual companies that will develop preclinical programs and move them to Phase II proof of concept using an...
07:00 , Apr 15, 2013 |  BC Week In Review  |  Company News

Sanofi Pharmaceuticals Inc., OrthoLogic sales and marketing update

The companies began co-promoting Hyalgan (sodium hyaluronate) in the U.S. to treat pain in osteoarthritis of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and to simple analgesics such...
07:00 , Aug 13, 2012 |  BC Week In Review  |  Company News

Capstone Therapeutics, LipimetiX deal

Capstone and LipimetiX formed a 60/40 JV, LipimetiX Development LLC, to develop LipimetiX's mimetics of apolipoprotein E (APOE) . LipimetiX has rights to the compounds from University of Alabama at Birmingham . Capstone will contribute...
08:00 , Jan 30, 2012 |  BC Week In Review  |  Company News

Capstone Therapeutics dermatology, pulmonary news

Capstone said it will cease development of its two compounds, AZX100 and TP508, to preserve cash and move towards winding down operations since it has not yet found a partner for AZX100. The company also...
08:00 , Jan 2, 2012 |  BioCentury  |  Finance

Small-fry squashed

Among last year's best-performing large cap biotechs were an acquiree and an acquirer: HCV play Pharmasset Inc. and Valeant Pharmaceuticals International Inc. Other big cap stocks also did well overall, while investors abandoned their small-...